MEDIPOST Co., Ltd. (KOSDAQ: 078160)

Market Cap	366.56B
Revenue (ttm)	69.86B
Net Income (ttm)	-10.82B
Shares Out	34.10M
EPS (ttm)	-332.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	218,575
Average Volume	313,555
Open	10,750
Previous Close	10,750
Day's Range	10,750 - 11,280
52-Week Range	5,450 - 15,180
Beta	0.35
RSI	47.80
Earnings Date	Jan 27, 2025

About MEDIPOST

MEDIPOST Co., Ltd. engages in the cord blood bank business in South Korea and internationally. The company operates through three divisions: Cord Blood Bank, Stem Cell Therapy, and Health Functional Food. It operates cord blood bank under the CELLTREE name. The company also offers CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell products, such as PNEUMOSTEM for the preventative treatment of bronchopulmonary dysplasia. Further, the co...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 308
• Stock Exchange: KOSDAQ
• Ticker Symbol: 078160

Financial Performance

In 2023, MEDIPOST's revenue was 68.64 billion, an increase of 6.92% compared to the previous year's 64.20 billion. Earnings were 5.84 billion, an increase of 90.31%.